Global Regulatory Pathways

International regulatory requirements for medical devices beyond FDA and EU MDR markets.

tools-only Updated Sep 29, 2026 7 repo stars

Research & Search

Install

Press C to copy

$ npx skillmds@latest add tools-only/global-regulatory-pathways

Installs into ~/.claude/skills (or .claude/skills inside a project). Restart Claude Code to pick it up.

＋ Add to plugin

README badge

[![SkillMD](https://skillmd.com/badge/tools-only/global-regulatory-pathways.svg)](https://skillmd.com/skills/tools-only/global-regulatory-pathways)

Trust & safety

2 of 3 audits passed

Last audited Sep 23, 2026 · commit b320d9a

Works with: Claude Code Claude.ai OpenAI Codex +

File contents

Global Regulatory Pathways

International regulatory requirements for medical devices beyond FDA and EU MDR markets.

Table of Contents

Canada (Health Canada)
Japan (PMDA)
China (NMPA)
Australia (TGA)
Brazil (ANVISA)
Market Entry Strategy

Canada (Health Canada)

Device Classification

Class	Risk Level	Examples	Review Type
I	Lowest	Tongue depressors, bandages	Establishment license only
II	Low-moderate	Contact lenses, pregnancy tests	Declaration of conformity
III	Moderate-high	Orthopedic implants, ventilators	Pre-market review
IV	Highest	Pacemakers, HIV tests	In-depth pre-market review

Medical Device License (MDL) Requirements

Class II-IV Devices:

Device license application via MDALL (Medical Devices Active License Listing)
Quality management system documentation (ISO 13485)
Device safety and effectiveness evidence
Canadian labeling requirements (French/English bilingual)
Canadian Medical Device Single Audit Program (CMDCAS) certificate

Review Timelines:

Class	Standard Review	Priority Review
II	15 days	N/A
III	60 days	30 days
IV	75 days	45 days

Key Requirements

Requirement	Details
QMS Audit	MDSAP or ISO 13485 audit by recognized body
UDI	Canadian UDI-DI required in MDALL
Labeling	Bilingual (English/French) mandatory
Incident Reporting	Mandatory problem reporting within 10-30 days
Post-Market	Annual license maintenance

Japan (PMDA)

Device Classification (Pharmaceutical and Medical Device Act)

Class	Japanese Term	Examples	Regulatory Path
I	General	Scalpels, X-ray film	Self-certification
II	Controlled	MRI, ultrasound	Third-party certification
III	Specially Controlled	Pacemaker leads, dialyzers	PMDA Shonin approval
IV	Specially Controlled	Pacemakers, artificial hearts	PMDA Shonin approval

Shonin Approval Process

Pre-Application:

Classification consultation with PMDA
Pre-submission meeting (recommended for Class III/IV)
Japanese clinical data requirements assessment
Marketing Authorization Holder (MAH) designation

Application Requirements:

Technical documentation per MHLW format
Japanese clinical data (bridging study may be required)
QMS compliance certificate (ISO 13485)
GCP compliance for clinical studies
Japanese labeling and IFU

Review Timelines:

Application Type	Standard	Priority
New Shonin	12 months	6 months
Partial Change	6-9 months	3-4 months

Special Considerations

Factor	Requirement
Clinical Data	Japanese patient data often required
MAH	Requires Japanese MAH or Designated MAH (D-MAH)
QMS	MHLW Minister certification or ISO 13485
Language	All documents in Japanese
Foreign Manufacturer	Accreditation required

China (NMPA)

Device Classification

Class	Risk Level	Examples	Regulatory Path
I	Low	Surgical instruments	Provincial filing
II	Moderate	Diagnostic ultrasound, ECG	Provincial registration
III	High	Pacemakers, implants	NMPA registration

Registration Requirements

Class II/III Registration:

Clinical evaluation or trial (China-specific requirements)
Product technical requirements document
Type testing by NMPA-designated lab
Quality management system (ISO 13485 + Chinese requirements)
Chinese agent appointment (CSRC holder)

Review Process:

Stage	Class II	Class III
Technical Review	60 working days	90 working days
Administrative Review	20 working days	20 working days
Registration Certificate	5 years validity	5 years validity

Key Requirements

Requirement	Details
Clinical Trial	Required for most Class III; China-specific data
Testing	NMPA-designated testing laboratory
Agent	Chinese Service Representative Certificate (CSRC) holder
Labeling	Simplified Chinese mandatory
QMS	Chinese GMP compliance in addition to ISO 13485

China Clinical Trial Requirements

Device Type	Clinical Requirement
First-of-kind	Full clinical trial in China
Well-established	Literature + clinical evaluation
Equivalent device	Comparative analysis + limited data

Australia (TGA)

Device Classification (TGO 41)

Class	Risk Level	Examples	Conformity Route
I	Lowest	Surgical retractors	Manufacturer declaration
I (measuring)	Low	Clinical thermometers	EU/MDSAP certificate
I (sterile)	Low	Sterile gloves	EU/MDSAP certificate
IIa	Low-moderate	Hearing aids, ultrasound	EU/MDSAP certificate
IIb	Moderate-high	Ventilators, X-ray	EU/MDSAP certificate
III	High	Pacemakers, implants	EU/MDSAP certificate
AIMD	Active implants	Cochlear implants	EU/MDSAP certificate

Australian Register of Therapeutic Goods (ARTG)

Registration Requirements:

Australian sponsor (manufacturer or importer)
Conformity assessment evidence (EU certificate or MDSAP)
Australian labeling compliance
Adverse event reporting system
ARTG application and fees

Pathways:

Pathway	Applicable Devices	Documentation
Conformity Assessment	All classes	EU/MDSAP certificates accepted
Comparable Overseas Regulator	Established devices	Recognition of FDA/EU approval
TGA Audit	No overseas certificate	TGA conducts assessment

Key Requirements

Requirement	Details
Sponsor	Australian-based sponsor mandatory
Conformity	EU MDR/IVDR or MDSAP certificate
Labeling	English, Australian-specific requirements
Incident Reporting	Mandatory within 48 hours (serious)
Annual Charges	Based on ARTG listing

Brazil (ANVISA)

Device Classification (RDC 185/2001)

Class	Risk Level	Examples	Registration
I	Low	Tongue depressors	Notification (cadastro)
II	Low-moderate	Wheelchairs, syringes	Notification (cadastro)
III	Moderate-high	Hemodialysis, implants	Registration (registro)
IV	High	Pacemakers, stents	Registration (registro)

Registration Process

Cadastro (Class I/II):

Brazilian Registration Holder (BRH) application
Technical documentation
Good Manufacturing Practice (GMP) certificate
Free sale certificate from country of origin

Registro (Class III/IV):

Full technical dossier submission
ANVISA GMP inspection (if not MDSAP)
Clinical data requirements
Brazilian labeling and IFU
Registration validity: 5 years (Class III) or 10 years (Class IV)

Key Requirements

Requirement	Details
BRH	Brazilian Registration Holder mandatory
GMP	ANVISA inspection or MDSAP certificate
INMETRO	Certification for specific device categories
Language	Portuguese labeling and IFU
Clinical	Brazilian clinical data may be required

Review Timelines:

Type	Standard	Priority
Cadastro	30-60 days	N/A
Registro	180-365 days	90-180 days

Market Entry Strategy

Prioritization Framework

Factor	Weight	Considerations
Market Size	25%	Revenue potential, growth rate
Regulatory Complexity	25%	Timeline, cost, local requirements
Competitive Landscape	20%	Existing players, differentiation
Reimbursement	20%	Payer coverage, pricing
Strategic Value	10%	Reference market, regional hub

Recommended Entry Sequence

Phase 1: Priority Markets (Year 1)

United States (FDA)
European Union (MDR)
Leverage for downstream approvals

Phase 2: Recognition Markets (Year 1-2)

Australia (TGA) - accepts EU/MDSAP
Canada (Health Canada) - MDSAP pathway
Faster approval using existing evidence

Phase 3: Major Markets (Year 2-3)

Japan (PMDA) - may require local clinical
China (NMPA) - local testing and clinical

Phase 4: Emerging Markets (Year 3+)

Brazil (ANVISA)
Other Latin America
Middle East, Southeast Asia

Documentation Efficiency

Document Type	Create Once	Localize Per Market
Technical file	Core technical documentation	Specific format requirements
Clinical data	Global clinical study	Local bridging studies
QMS certificate	ISO 13485 / MDSAP	Market-specific audits
Labeling	Master label content	Language, local requirements

Common Pitfalls

Pitfall	Impact	Prevention
Underestimating local clinical requirements	12-24 month delay	Early regulatory intelligence
Inadequate in-country representation	Registration rejection	Qualified local partner
Language/labeling non-compliance	Market rejection	Professional translation review
Ignoring post-market requirements	License suspension	Establish vigilance system
Sequential vs. parallel submissions	Extended timeline	Plan parallel submissions where possible

---name: global-regulatory-pathwaysdescription: International regulatory requirements for medical devices beyond FDA and EU MDR markets.---# Global Regulatory PathwaysInternational regulatory requirements for medical devices beyond FDA and EU MDR markets.---## Table of Contents- [Canada (Health Canada)](#canada-health-canada)- [Japan (PMDA)](#japan-pmda)- [China (NMPA)](#china-nmpa)- [Australia (TGA)](#australia-tga)- [Brazil (ANVISA)](#brazil-anvisa)- [Market Entry Strategy](#market-entry-strategy)---## Canada (Health Canada)### Device Classification| Class | Risk Level | Examples | Review Type ||-------|------------|----------|-------------|| I | Lowest | Tongue depressors, bandages | Establishment license only || II | Low-moderate | Contact lenses, pregnancy tests | Declaration of conformity || III | Moderate-high | Orthopedic implants, ventilators | Pre-market review || IV | Highest | Pacemakers, HIV tests | In-depth pre-market review |### Medical Device License (MDL) Requirements**Class II-IV Devices:**1. Device license application via MDALL (Medical Devices Active License Listing)2. Quality management system documentation (ISO 13485)3. Device safety and effectiveness evidence4. Canadian labeling requirements (French/English bilingual)5. Canadian Medical Device Single Audit Program (CMDCAS) certificate**Review Timelines:**| Class | Standard Review | Priority Review ||-------|-----------------|-----------------|| II | 15 days | N/A || III | 60 days | 30 days || IV | 75 days | 45 days |### Key Requirements| Requirement | Details ||-------------|---------|| QMS Audit | MDSAP or ISO 13485 audit by recognized body || UDI | Canadian UDI-DI required in MDALL || Labeling | Bilingual (English/French) mandatory || Incident Reporting | Mandatory problem reporting within 10-30 days || Post-Market | Annual license maintenance |---## Japan (PMDA)### Device Classification (Pharmaceutical and Medical Device Act)| Class | Japanese Term | Examples | Regulatory Path ||-------|---------------|----------|-----------------|| I | General | Scalpels, X-ray film | Self-certification || II | Controlled | MRI, ultrasound | Third-party certification || III | Specially Controlled | Pacemaker leads, dialyzers | PMDA Shonin approval || IV | Specially Controlled | Pacemakers, artificial hearts | PMDA Shonin approval |### Shonin Approval Process**Pre-Application:**1. Classification consultation with PMDA2. Pre-submission meeting (recommended for Class III/IV)3. Japanese clinical data requirements assessment4. Marketing Authorization Holder (MAH) designation**Application Requirements:**- Technical documentation per MHLW format- Japanese clinical data (bridging study may be required)- QMS compliance certificate (ISO 13485)- GCP compliance for clinical studies- Japanese labeling and IFU**Review Timelines:**| Application Type | Standard | Priority ||------------------|----------|----------|| New Shonin | 12 months | 6 months || Partial Change | 6-9 months | 3-4 months |### Special Considerations| Factor | Requirement ||--------|-------------|| Clinical Data | Japanese patient data often required || MAH | Requires Japanese MAH or Designated MAH (D-MAH) || QMS | MHLW Minister certification or ISO 13485 || Language | All documents in Japanese || Foreign Manufacturer | Accreditation required |---## China (NMPA)### Device Classification| Class | Risk Level | Examples | Regulatory Path ||-------|------------|----------|-----------------|| I | Low | Surgical instruments | Provincial filing || II | Moderate | Diagnostic ultrasound, ECG | Provincial registration || III | High | Pacemakers, implants | NMPA registration |### Registration Requirements**Class II/III Registration:**1. Clinical evaluation or trial (China-specific requirements)2. Product technical requirements document3. Type testing by NMPA-designated lab4. Quality management system (ISO 13485 + Chinese requirements)5. Chinese agent appointment (CSRC holder)**Review Process:**| Stage | Class II | Class III ||-------|----------|-----------|| Technical Review | 60 working days | 90 working days || Administrative Review | 20 working days | 20 working days || Registration Certificate | 5 years validity | 5 years validity |### Key Requirements| Requirement | Details ||-------------|---------|| Clinical Trial | Required for most Class III; China-specific data || Testing | NMPA-designated testing laboratory || Agent | Chinese Service Representative Certificate (CSRC) holder || Labeling | Simplified Chinese mandatory || QMS | Chinese GMP compliance in addition to ISO 13485 |### China Clinical Trial Requirements| Device Type | Clinical Requirement ||-------------|---------------------|| First-of-kind | Full clinical trial in China || Well-established | Literature + clinical evaluation || Equivalent device | Comparative analysis + limited data |---## Australia (TGA)### Device Classification (TGO 41)| Class | Risk Level | Examples | Conformity Route ||-------|------------|----------|------------------|| I | Lowest | Surgical retractors | Manufacturer declaration || I (measuring) | Low | Clinical thermometers | EU/MDSAP certificate || I (sterile) | Low | Sterile gloves | EU/MDSAP certificate || IIa | Low-moderate | Hearing aids, ultrasound | EU/MDSAP certificate || IIb | Moderate-high | Ventilators, X-ray | EU/MDSAP certificate || III | High | Pacemakers, implants | EU/MDSAP certificate || AIMD | Active implants | Cochlear implants | EU/MDSAP certificate |### Australian Register of Therapeutic Goods (ARTG)**Registration Requirements:**1. Australian sponsor (manufacturer or importer)2. Conformity assessment evidence (EU certificate or MDSAP)3. Australian labeling compliance4. Adverse event reporting system5. ARTG application and fees**Pathways:**| Pathway | Applicable Devices | Documentation ||---------|-------------------|---------------|| Conformity Assessment | All classes | EU/MDSAP certificates accepted || Comparable Overseas Regulator | Established devices | Recognition of FDA/EU approval || TGA Audit | No overseas certificate | TGA conducts assessment |### Key Requirements| Requirement | Details ||-------------|---------|| Sponsor | Australian-based sponsor mandatory || Conformity | EU MDR/IVDR or MDSAP certificate || Labeling | English, Australian-specific requirements || Incident Reporting | Mandatory within 48 hours (serious) || Annual Charges | Based on ARTG listing |---## Brazil (ANVISA)### Device Classification (RDC 185/2001)| Class | Risk Level | Examples | Registration ||-------|------------|----------|--------------|| I | Low | Tongue depressors | Notification (cadastro) || II | Low-moderate | Wheelchairs, syringes | Notification (cadastro) || III | Moderate-high | Hemodialysis, implants | Registration (registro) || IV | High | Pacemakers, stents | Registration (registro) |### Registration Process**Cadastro (Class I/II):**- Brazilian Registration Holder (BRH) application- Technical documentation- Good Manufacturing Practice (GMP) certificate- Free sale certificate from country of origin**Registro (Class III/IV):**- Full technical dossier submission- ANVISA GMP inspection (if not MDSAP)- Clinical data requirements- Brazilian labeling and IFU- Registration validity: 5 years (Class III) or 10 years (Class IV)### Key Requirements| Requirement | Details ||-------------|---------|| BRH | Brazilian Registration Holder mandatory || GMP | ANVISA inspection or MDSAP certificate || INMETRO | Certification for specific device categories || Language | Portuguese labeling and IFU || Clinical | Brazilian clinical data may be required |**Review Timelines:**| Type | Standard | Priority ||------|----------|----------|| Cadastro | 30-60 days | N/A || Registro | 180-365 days | 90-180 days |---## Market Entry Strategy### Prioritization Framework| Factor | Weight | Considerations ||--------|--------|----------------|| Market Size | 25% | Revenue potential, growth rate || Regulatory Complexity | 25% | Timeline, cost, local requirements || Competitive Landscape | 20% | Existing players, differentiation || Reimbursement | 20% | Payer coverage, pricing || Strategic Value | 10% | Reference market, regional hub |### Recommended Entry Sequence**Phase 1: Priority Markets (Year 1)**- United States (FDA)- European Union (MDR)- Leverage for downstream approvals**Phase 2: Recognition Markets (Year 1-2)**- Australia (TGA) - accepts EU/MDSAP- Canada (Health Canada) - MDSAP pathway- Faster approval using existing evidence**Phase 3: Major Markets (Year 2-3)**- Japan (PMDA) - may require local clinical- China (NMPA) - local testing and clinical**Phase 4: Emerging Markets (Year 3+)**- Brazil (ANVISA)- Other Latin America- Middle East, Southeast Asia### Documentation Efficiency| Document Type | Create Once | Localize Per Market ||---------------|-------------|---------------------|| Technical file | Core technical documentation | Specific format requirements || Clinical data | Global clinical study | Local bridging studies || QMS certificate | ISO 13485 / MDSAP | Market-specific audits || Labeling | Master label content | Language, local requirements |### Common Pitfalls| Pitfall | Impact | Prevention ||---------|--------|------------|| Underestimating local clinical requirements | 12-24 month delay | Early regulatory intelligence || Inadequate in-country representation | Registration rejection | Qualified local partner || Language/labeling non-compliance | Market rejection | Professional translation review || Ignoring post-market requirements | License suspension | Establish vigilance system || Sequential vs. parallel submissions | Extended timeline | Plan parallel submissions where possible |

tools-only/X-Skills/tree/main/research/857-global-regulatory-pathways_a271cb0e commit b320d9afba

Frequently asked questions

npx skillmds@latest add tools-only/global-regulatory-pathways